Biotech using PEGylation drug-delivery technology; developing immunology drug rezpegaldesleukin after past oncology setbacks.
Biotech using PEGylation drug-delivery technology; developing immunology drug rezpegaldesleukin after past oncology setbacks.
Has no medicine of its own on sale, so income is limited to royalties and milestone payments from partners whose drugs use its PEGylation technology, with the rest funded from cash raised from investors. After the 2022 failure of its bempegaldesleukin cancer drug with Bristol Myers Squibb, it shrank to focus on immune-disease drugs.
Moat: narrow (IP / patents, process know-how). PEGylation chemistry know-how is real but recent late-stage trial failures have weakened its moat.
Headquarters: San Francisco, California, US · Founded: 1990 · Employees: 63
Size Nektar Therapeutics (NKTR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 2132nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $34.42 on 18 Nov 2026.
Performance Over six months the shares fell 50.5%, against -11.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 16.6% over the last twelve months (peer median +5.9%); the operating margin is -303.6% (peer median 0.8%).
Valuation It trades at 13.3× enterprise value to sales against a peer median of 7.6× (4th most expensive of 18).
Capital Return on invested capital runs 46.0 points below its cost of capital (11.7% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $52.2M | $55.2M | $98.4M | $90.1M | $92.1M |
| Revenue growth | — | -44% | +9% | -2% | — |
| Gross profit | $51.5M | $54.2M | $66.5M | $53.5M | $62.9M |
| EBITDA | -$158M | -$133M | -$129M | -$130M | -$228M |
| Net income | -$177M | -$164M | -$119M | -$276M | -$368M |
| Free cash flow | -$257M | -$209M | -$177M | -$193M | -$310M |
| Capital expenditure | $528,000 | $171,000 | $1.47M | $865,000 | $5.68M |
| Total debt | $129M | $149M | $194M | $230M | $258M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nektar Therapeutics NKTR | $1.18B | -50% | -17% | -304% | 13.3× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NKTR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.2% | -1.6% | 5th lowest of 21 |
| 6-month return | -50.5% | -11.8% | 2nd lowest of 20 |
| Distance from 52-week high | -68.4% | -36.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | -16.6% | +5.9% | 4th lowest of 18 |
| Operating margin | -303.6% | 0.8% | 2nd lowest of 18 |
| EV / Sales | 13.3× | 7.6× | 4th most expensive of 18 |
| ROIC minus cost of capital | -46.0 pp | -7.5 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | 13.3× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |